litronesib (KF 89617) / Kyowa Kirin, Eli Lilly - LARVOL DELTA

Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies. (PubMed, Future Sci OA) - "In this review, we track the medicinal chemistry developmental stages of KSP inhibitors. Moreover, we address the challenges that are faced during the development of KSP inhibitor therapy for cancer and future insights for the latest advances in research that are directed to find active KSP inhibitor drugs."

Journal • Review • Oncology

Role of KSP inhibitors as anti-cancer therapeutics: an update. (PubMed, Anticancer Agents Med Chem) - "Drugs such as filanesib, litronesib, ispinesib have entered clinical trials, the most advanced phase explored being Phase II. KSP inhibitors have exhibited promising results; however, continued exploration is greatly required to establish the clinical potential of KSP inhibitors."

Journal • Allergy • Oncology • Pain

Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing. (PubMed, Viruses) - "To that end, using three bacteria-based assays, we screened a library of 2839 approved-for-human-use drugs and identified the following potential channel-blockers: Capreomycin, Pentamidine, Spectinomycin, Kasugamycin, Plerixafor, Flumatinib, Litronesib, Darapladib, Floxuridine and Fludarabine. The stage is now set for examining the activity of these compounds in detailed electrophysiological studies and their impact on the whole virus with appropriate biosafety measures."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - P2; N=103; Completed; Sponsor: Eli Lilly and Company; N=250 ➔ 103

Clinical • Enrollment change

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - P2; N=250; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Clinical • Trial completion